The 34 European Medical Societies that the BioMed Alliance represents believe that reform of the regulatory system is necessary, as some of the unintended consequences of the MDR and IVDR implementation led to high costs and reduced availability of essential devices and diagnostics .
BioMed Alliance
Other · Belgium · EU Transparency Register 876034021209-88
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 311 trade unions and professional associations on this site, they rank #61 by legislative files engaged — a count of participation, not a measure of influence.
Declares membership of
- http://www.biomedeurope.org/about/members.html
- https://www.biomedeurope.org/about/cooperation.html
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Trade unions and professional associations
- Registered as
- Biomedical Alliance in Europe (the BioMed Alliance)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track BioMed in PolicySpeak: request access →
Work at BioMed Alliance? so we know who speaks for it.
Their record over time
BioMed Alliance filed 5 positions between 10 Sept 2025 and 5 Aug 2026, across 4 of the 326 legislative files tracked here, attaching a full position paper 5 times.
What they argued
--Please find our response to the call for evidence attached-- SUMMARY: The BioMed Alliance supports the objectives of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) to safeguard patient safety and ensure innovation. However, implementation has revealed significant challenges that must be addressed to protect patients access to safe, effective, and innovative technologies.
The BioMed Alliance welcomes the European Commissions initiative to develop a European Biotech Act as an important opportunity to strengthen Europes biotechnology ecosystem, enhance its global competitiveness and accelerate the translation of scientific innovation into solutions that benefit society.
The BioMed Alliance welcomes the European Commissions intention to improve research in Europe through the development of a new European Research Area Act. We hope that the Act will play a role in supporting the fifth freedom, the free movement of researchers, scientific knowledge, and technology in the EU single market, but it needs to be fit for purpose and not add unnecessary regulatory complexity.
We welcome the European Commissions intention to review the complementarity, efficiency and effectiveness of the EU digital rulebook. The EU digital sector, and particularly the digital health sector, are burdened by a large number of overlapping regulatory frameworks that enhance regulatory complexity and put a burden on different actors in the system.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- Wirtschaftskammer Österreich · 3 files in common
- BEUC - The European Consumer Organisation · 3 files in common
- MedTech Europe · 3 files in common
- HOPE (EUROPEAN HOSPITAL AND HEALTHCARE FEDERATION) · 3 files in common
Showing 5 of 66.
Is this your organization?
Everything on this page comes from BioMed Alliance’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.